EXL01 is named as an intervention in 4 current clinical trials in our France register. 4 are recruiting patients now. The most common phase is Phase 1/2. The sponsor with the most trials is Hospices Civils de Lyon (1). The most-studied condition is Clostridioides Difficile Infection.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer
NCT06253611 · ClinicalTrials.gov ↗ · Gastric Cancer
|
Phase 2 | Recruiting | GERCOR - Multidisciplinary Oncology Cooperative Group | France |
|
Microbiota Modification for Immuno-oncology in Hepatocellular Carcinoma
NCT06551272 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma
|
Phase 2 | Recruiting | Center Eugene Marquis | France |
|
Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients
NCT06306014 · ClinicalTrials.gov ↗ · Clostridioides Difficile Infection, Recurrent Infection
|
Phase 1/2 | Recruiting | Hospices Civils de Lyon | France |
|
EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy.
NCT06448572 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer
|
Phase 1/2 | Recruiting | University Hospital, Lille | France |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Hospices Civils de Lyon | 1 |
| Center Eugene Marquis | 1 |
| GERCOR - Multidisciplinary Oncology Cooperative Group | 1 |
| University Hospital, Lille | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in France | 4 | 4 |
A trial with sites in more than one country appears in each of those registers.
4 current trials in our France register name EXL01 as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 4 of the 4 trials are recruiting: 4 with sites in France. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Hospices Civils de Lyon (1), Center Eugene Marquis (1), GERCOR - Multidisciplinary Oncology Cooperative Group (1) and University Hospital, Lille (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how EXL01 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how EXL01 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists EXL01 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.